Table 2 Baseline characteristics and follow-up of each patient (continued)
Case 7 | Case 8 | Case 9 | Case 10 | Case 11 | |
|---|---|---|---|---|---|
Sex | male | female | female | male | male |
Age (years) | 60 | 54 | 56 | 61 | 72 |
Hypertension | yes | no | no | yes | yes |
Diabetes | no | no | yes | yes | yes |
Hyperlipidemia | no | no | yes | yes | no |
CAD | yes | no | yes | yes | no |
Prior MI | no | no | no | no | no |
Smoking | yes | no | no | yes | no |
Previous medication | |||||
Beta-blocker | yes | no | no | no | yes |
ACEI or ARB | no | no | no | yes | no |
CCB | yes | no | no | yes | yes |
Statin | no | no | yes | no | no |
Cancer type | lung | lung | colorectum | liver | colorectum |
ICI type | P | P | S | P & A | S |
1st ICI to pacing | 20 days | 213 days | 35 days | 53 days | 24 days |
Dyspnea | yes | yes | no | no | no |
Chest pain or tightness | yes | yes | yes | no | no |
Myasthenia | yes | no | no | yes | yes |
Myalgia | yes | no | no | yes | yes |
Blepharoptosis | no | no | no | yes | yes |
Diplopia | yes | no | no | no | no |
Syncope | yes | no | yes | no | no |
VT | yes | yes | no | no | no |
HF | yes | yes | no | no | no |
Cardiac Shock | no | yes | no | no | no |
AVB | Adv. | Comp. | Comp. | Comp. | Comp. |
LVEF (%) | 63 | 23 | 62 | 50 | 68 |
cTnI (µg/L) | 39.8 | 12.2 | 4.6 | 0.9 | 7.1 |
CK (U/L) | 18325.0 | 173.0 | 73.0 | 18189.0 | 712 |
CKMB (µg/L) | 163.6 | 21.6 | 16.5 | 323.7 | 85.6 |
NT-proBNP (pg/ml) | 2293.0 | 6768.0 | 1922.0 | 917.0 | 867.0 |
SCr, µmol/L | 86.0 | 38.0 | 56.0 | 87.0 | 62.0 |
hsCRP, mg/L | 66.0 | 37.8 | 0.5 | 15.5 | 0.8 |
Myositis | yes | no | no | yes | yes |
Hepatitis | no | no | no | no | no |
Treatments | |||||
Intravenous isoproterenol | yes | no | yes | no | yes |
MP | yes | yes | yes | yes | yes |
MP pulse | yes | yes | yes | no | no |
IVIG | yes | yes | yes | yes | yes |
Tocilizumab | yes | yes | no | no | yes |
ACEI or ARB | no | no | no | yes | no |
CCB | no | no | no | yes | yes |
Invasive ventilation | no | no | no | no | no |
Vasoactive drugs | no | yes | no | no | no |
TPM lead | passive | active | active | active | active |
Vein access | femoral | subclavian | internal jugular | internal jugular | internal jugular |
RV pacing site | apex | septum | septum | septum | septum |
RV T(V@0.4ms) | 2.5 | 0.8 | 0.3 | 0.8 | 1.8 |
RV S(mV) | NA | 13.6 | 4.0 | 27.4 | 4.6 |
RV I(Ω) | NA | 606 | 970 | 714 | 1098 |
Follow-up(days) | 561 | 1 | 211 | 187 | 121 |
AVC recover | yes | no | yes | yes | no |
PPM | no | no | no | no | yes |
Primary Endpoint | survival | dead | survival | survival | survival |